MBIO News and Press, Mustang Bio Inc. From 08/17/22

The following slide deck was published by Mustang Bio, Inc. in conjunction with this event. For further details see: Mustang Bio (MBIO) Corporate Presentation - Slideshow

Mustang Bio press release ( NASDAQ: MBIO ): Q2 GAAP EPS of -$0.19 beats by $0.02 . As of June 30, 2022, Mustang’s cash and cash equivalents and restricted cash totaled $108.4M. For further details see: Mustang Bio GAAP EPS of -$0.19 beats by $0.02

WORCESTER, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

WORCESTER, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

Buying Penny Stocks on June 23rd? Here’s What You Need to Know With another day of trading penny stocks, there is a lot for investors to consider. As a result, investors need to understand exactly what is going on and how to take advantage. This involves having a trading strategy...

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Mustang Bio's (NASDAQ:MBIO) CAR T cell therapy MB-106 to treat Waldenstrom macroglobulinemia (WM). WM is rare cancer that begins when the bone marrow produces too many abnormal white blood cells. WM ...

WORCESTER, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

An autologous CAR T cell therapy developed by clinical-stage biotech Mustang Bio (NASDAQ:MBIO) in collaboration with Fred Hutchinson Cancer Center worked effectively with a favorable safety profile in follicular lymphoma, the company said Monday. Disclosing updated interim data from an ongoin...

94% overall response rate and 78% complete response rate in patients with FL, including complete response in a patient previously treated with CD19-targeted CAR T therapy 100% overall response rate in other B-cell non-Hodgkin lymphomas including Waldenstrom macroglobulinemia and...

Mustang Bio (NASDAQ:MBIO) said on Thursday treatment with its lentiviral gene therapy, MB-107, for X-linked severe combined immunodeficiency (XSCID) in newly diagnosed infants under the age of two support plans to begin a Phase 2 trial in the second half of this year. The data includes 2...